Meetings; Sunshine Act, 6921 [E9-2970]

Download as PDF Federal Register / Vol. 74, No. 27 / Wednesday, February 11, 2009 / Notices 1301.34(a), this is notice that on January 6, 2009, Roche Diagnostics Operations Inc., Attn: Regulatory Compliance, 9115 Hague Road, Indianapolis, Indiana 46250, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedules I and II: Drug Schedule Lysergic acid diethylamide (7315) Tetrahydrocannabinols (7370) ..... Alphamethadol (9605) .................. Cocaine (9041) ............................. Ecgonine (9180) ........................... Methadone (9250) ........................ Morphine (9300) ........................... I I I II II II II mstockstill on PROD1PC66 with NOTICES The company plans to import the listed controlled substances for the manufacture of diagnostic products for distribution to its customers. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43, and in such form as prescribed by 21 CFR 1316.47. Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than March 13, 2009. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745–46), all applicants for registration to import a basic class of any controlled substance in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. Dated: February 5, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–2904 Filed 2–10–09; 8:45 am] DEPARTMENT OF JUSTICE 17:58 Feb 10, 2009 Jkt 217001 FEDERAL MINE SAFETY AND HEALTH REVIEW COMMISSION Drug Enforcement Administration Meetings; Sunshine Act Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on January 6, 2009, Siegfried (USA), Inc., 33 Industrial Park Road, Pennsville, New Jersey 08070, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug Schedule Dihydromorphine (9145) ............... Amphetamine (1100) .................... Methylphenidate (1724) ................ Amobarbital (2125) ....................... Pentobarbital (2270) ..................... Secobarbital (2315) ...................... Glutethimide (2550) ...................... Codeine (9050) ............................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Methadone (9250) ........................ Methadone intermediate (9254) ... Dextropropoxyphene, bulk (nondosage forms) (9273). Morphine (9300) ........................... Oripavine (9330) ........................... Oxymorphone (9652) ................... I II II II II II II II II II II II II II II II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than April 13, 2009. Dated: February 5, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–2910 Filed 2–10–09; 8:45 am] BILLING CODE 4410–09–P BILLING CODE 4410–09–P VerDate Nov<24>2008 6921 PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 February 2, 2009. TIME AND DATE: 10 a.m., Thursday, February 12, 2009. PLACE: The Richard V. Backley Hearing Room, 9th Floor, 601 New Jersey Avenue, NW., Washington, DC. STATUS: Open. MATTERS TO BE CONSIDERED: The Commission will consider and act upon the following in open session: Secretary of Labor v. SCP Investments, LLC, Docket Nos. SE 2006–148–M and SE 2006–163–M. (Issues include whether the Administrative Law Judge properly concluded that certain citations and orders issued to the operator should be vacated because the MSHA inspector did not allow the operator to exercise any walkaround rights during the inspection in question.) Any person attending this meeting who requires special accessibility features and/or auxiliary aids, such as sign language interpreters, must inform the Commission in advance of those needs. Subject to 29 CFR 2706.150(a)(3) and 2706.160(d). FOR FURTHER INFORMATION CONTACT: Jean Ellen (202) 434–9950 / (202) 708–9300 for TDD Relay / 1–800–877–8339 for toll free. Jean H. Ellen, Chief Docket Clerk. [FR Doc. E9–2970 Filed 2–9–09; 11:15 am] BILLING CODE 6735–01–P NATIONAL FOUNDATION ON THE ARTS AND THE HUMANITIES Institute of Museum and Library Services; Sunshine Act Meeting of the National Museum and Library Services Board AGENCY: Institute of Museum and Library Services (IMLS), NFAH. ACTION: Notice of meeting. SUMMARY: This notice sets forth the agenda of the forthcoming meeting of the National Museum and Library Services Board. This notice also describes the function of the Board. Notice of the meeting is required under the Sunshine in Government Act. Time and Date: Wednesday, February 18, 2009 from 1:30 p.m. to 4:30 p.m. Agenda: Sixteenth National Museum and Library Services Board Meeting: I. Welcome. II. Approval of Minutes. E:\FR\FM\11FEN1.SGM 11FEN1

Agencies

[Federal Register Volume 74, Number 27 (Wednesday, February 11, 2009)]
[Notices]
[Page 6921]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-2970]


=======================================================================
-----------------------------------------------------------------------

FEDERAL MINE SAFETY AND HEALTH REVIEW COMMISSION


Meetings; Sunshine Act

February 2, 2009.

TIME AND DATE: 10 a.m., Thursday, February 12, 2009.

PLACE: The Richard V. Backley Hearing Room, 9th Floor, 601 New Jersey 
Avenue, NW., Washington, DC.

STATUS: Open.

MATTERS TO BE CONSIDERED: The Commission will consider and act upon the 
following in open session: Secretary of Labor v. SCP Investments, LLC, 
Docket Nos. SE 2006-148-M and SE 2006-163-M. (Issues include whether 
the Administrative Law Judge properly concluded that certain citations 
and orders issued to the operator should be vacated because the MSHA 
inspector did not allow the operator to exercise any walkaround rights 
during the inspection in question.)
    Any person attending this meeting who requires special 
accessibility features and/or auxiliary aids, such as sign language 
interpreters, must inform the Commission in advance of those needs. 
Subject to 29 CFR 2706.150(a)(3) and 2706.160(d).

FOR FURTHER INFORMATION CONTACT: Jean Ellen (202) 434-9950 / (202) 708-
9300 for TDD Relay / 1-800-877-8339 for toll free.

Jean H. Ellen,
Chief Docket Clerk.
 [FR Doc. E9-2970 Filed 2-9-09; 11:15 am]
BILLING CODE 6735-01-P